Ott et al., 2010 - Google Patents
Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's diseaseOtt et al., 2010
View PDF- Document ID
- 6119253980401701196
- Author
- Ott B
- Cohen R
- Gongvatana A
- Okonkwo O
- Johanson C
- Stopa E
- Donahue J
- Silverberg G
- Alzheimer's Disease Neuroimaging Initiative
- et al.
- Publication year
- Publication venue
- Journal of Alzheimer's Disease
External Links
Snippet
The frequent co-occurrence of Alzheimer's disease (AD) pathology in patients with normal pressure hydrocephalus suggests a possible link between ventricular dilation and AD. If enlarging ventricles serve as a marker of faulty cerebrospinal fluid (CSF) clearance …
- 206010001897 Alzheimer's disease 0 title abstract description 103
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—G01N2333/4701
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ott et al. | Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease | |
| Ferman et al. | The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies | |
| Jack Jr | Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play | |
| Sorbi et al. | EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia | |
| Fjell et al. | What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus | |
| Mueller et al. | Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI) | |
| Toledo et al. | Clinical and multimodal biomarker correlates of ADNI neuropathological findings | |
| Wahlund et al. | Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients | |
| Gold et al. | White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults | |
| Cedazo-Minguez et al. | Biomarkers for Alzheimer’s disease and other forms of dementia: clinical needs, limitations and future aspects | |
| Josephson et al. | The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia | |
| Mistur et al. | Current challenges for the early detection of Alzheimer's disease: brain imaging and CSF studies | |
| Dallaire-Théroux et al. | Radiological-pathological correlation in Alzheimer’s disease: systematic review of antemortem magnetic resonance imaging findings | |
| Khan | Biomarkers in Alzheimer's disease | |
| Mattsson et al. | Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults | |
| Morris et al. | Role of biomarkers in studies of presymptomatic Alzheimer’s disease | |
| Ashford et al. | Imaging the Alzheimer brain | |
| Mao et al. | White matter hyperintensities and patterns of atrophy in early onset Alzheimer’s disease with causative gene mutations | |
| Yu et al. | NODDI in gray matter is a sensitive marker of aging and early AD changes | |
| Nabizadeh et al. | Plasma p-tau181 associated with structural changes in mild cognitive impairment | |
| Cummings | Clinical evaluation as a biomarker for Alzheimer's disease | |
| Steinerman et al. | Laboratory biomarkers in Alzheimer’s disease | |
| Levine et al. | Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults | |
| Nabizadeh et al. | CSF total tau, plasma and CSF p tau 181 associated with structural changes in the early stage of Alzheimer's disease | |
| Cohen et al. | Cerebrospinal Fluid Biomarkers of Neurodegenerative and Ventricular Changes in the Elderly |